3-Methoxytyramine (3-MT) is a metabolite of the neurotransmitter dopamine and serves as a significant biomarker in various medical contexts.
In neuroblastoma, a childhood cancer, elevated levels of urinary 3-MT at diagnosis are indicative of high-risk disease and poor prognosis. This elevation reflects increased MYC activity and MYCN amplification in tumor cells, both of which drive tumor growth and progression.
High 3-MT levels correlate with a specific gene expression pattern linked to MYC activity, known as the 3-MT gene signature, which predicts poor survival even in low-risk patients.
Elevated 3-MT levels have also been observed in patients with pheochromocytoma, making it a useful marker for diagnosing and monitoring this adrenal gland tumor.
Measuring urinary 3-MT provides a non-invasive method to assess MYC activity, aiding in risk assessment and potentially guiding treatment strategies.
Additionally, 3-MT's role extends beyond being a mere dopamine byproduct; it acts as a neuromodulator influencing behavior through the trace amine-associated receptor 1 (TAAR1), with implications for conditions like Parkinson's disease and schizophrenia.
3-Methoxytyramine (3MT) is a biomarker for MYC activity and poor prognosis in neuroblastoma, a type of childhood cancer.
It is a metabolite of the neurotransmitter dopamine, produced by the enzyme dopamine beta-hydroxylase.
Elevated levels of 3MT in urine at the time of neuroblastoma diagnosis are associated with high-risk disease and poor clinical outcome. These high urinary 3MT levels reflect increased MYC activity and MYCN amplification in the tumor cells. MYC and MYCN are oncogenes that drive tumor growth and progression when overexpressed.
A gene signature derived from the differentially expressed genes associated with high 3MT levels can predict poor survival, even in low-risk neuroblastoma patients.
Tumors from patients with elevated urinary 3MT show strong MYCN protein expression but weak dopamine beta-hydroxylase expression, linking MYC activity to catecholamine biosynthesis and 3MT levels.
Measuring urinary 3MT at diagnosis can assist in assessing risk and prognosis in neuroblastoma patients.
In summary, 3MT is a promising biomarker that reflects the underlying biology of high-risk neuroblastoma driven by MYC/MYCN oncogene activity. Elevated urinary 3MT levels indicate poor prognosis, making it a clinically useful marker for risk stratification.
Elevated levels of 3-MT in urine are associated with poor prognosis in neuroblastoma patients, reflecting increased MYC activity in tumors.
This was confirmed in both retrospective and prospective patient cohorts, where high urinary 3-MT levels correlated with a specific gene expression pattern, termed the 3-MT gene signature. This signature includes eight differentially expressed genes that predict poor clinical outcomes and are linked to MYC activity.
The MYC gene encodes a transcription factor that regulates cell growth, proliferation, and apoptosis. MYC proteins bind to DNA, influencing the expression of numerous genes essential for cell cycle progression and metabolism.
In neuroblastoma, high MYC activity leads to more aggressive tumor behavior and poorer prognosis.
The study by Verly et. al. found that tumors with elevated urinary 3-MT levels exhibited strong MYCN (a MYC gene family member) staining and weak dopamine β-hydroxylase expression, linking MYC activity to altered catecholamine biosynthesis. [18.]
Thus, measuring urinary 3-MT levels can provide a non-invasive method to assess MYC activity in neuroblastoma, aiding in risk assessment and potentially guiding treatment strategies that target MYC signaling pathways.
The biochemistry and physiology of 3-MT (3-methoxytyramine) are closely tied to the metabolism of catecholamines, particularly dopamine, in the body.
3-MT is formed through the O-methylation of dopamine by the enzyme catechol-O-methyltransferase (COMT). This process occurs primarily in the extraneuronal spaces of various tissues, including the brain, adrenal glands, and other organs.
The resulting 3-MT is then further metabolized by monoamine oxidase (MAO) enzymes, ultimately leading to the formation of vanillylmandelic acid (VMA), which is excreted in urine.
Recent research reveals that 3-methoxytyramine (3-MT), a major metabolite of dopamine (DA) that was once thought to be biologically inactive, acts as a neuromodulator to independently influence behavior through the trace amine-associated receptor 1 (TAAR1).
In one study 3-MT was found to induce complex abnormal movements and behaviors in dopamine-deficient and normal mice. These findings highlight 3-MT's role beyond being a mere dopamine byproduct, suggesting it impacts movement control and signaling pathways in the brain.
The study suggests that 3-MT's neuromodulatory role, facilitated by TAAR1 activation, could be significant in conditions with abnormal dopaminergic transmission such as Parkinson's disease and schizophrenia.
Elevated 3-MT levels might contribute to side effects in Parkinson's treatment and could be implicated in schizophrenia's pathophysiology.
Elevated levels of 3-MT have been observed in patients with pheochromocytoma, a rare tumor of the adrenal gland that secretes excessive amounts of catecholamines. In these cases, 3-MT measurement can aid in the diagnosis and monitoring of the disease. [1.]
Additionally, increased 3-MT levels have been reported in neuroblastoma, a cancer of the sympathetic nervous system that primarily affects children. [18.]
Alterations in 3-MT levels have also been implicated in neurological disorders, such as Parkinson's disease and schizophrenia, where dopaminergic dysfunction plays a role. However, the clinical utility of 3-MT as a biomarker in these conditions requires further investigation.
Increased or decreased levels of 3-MT may correlate with symptoms of dopamine excess and deficiency.
Symptoms of excessive dopamine can have various manifestations, including:
Physiological Symptoms of Excessive Catecholamine Production [15., 16.]
Impulsivity and Poor Impulse Control [14.]
Aggression and Agitation [14., 16.]
Hyperactivity and Restlessness [16.]
Mania and Psychosis [16.]
Sleep Disturbances [8.]
Addiction and Compulsive Behaviors [14.]
Low dopamine may manifest in physical or mental symptoms. Of note, Parkinson’s disease is characterized by low levels of dopamine.
An age-related decline in available dopamine has also been noted. [11.]
Parkinson’s Disease [4., 16.]
Hypotension and Cardiac Issues [16.]
Neuropsychiatric Symptoms [4., 16.]
Cognitive Symptoms [4., 16.]
Hormonal and Endocrine Effects [4.]
Potential Withdrawal Symptoms: [4., 16.]
The measurement of 3-MT typically involves the collection of urine or plasma samples from patients. Blood testing requires a venipuncture. Urine samples are typically collected over 24 hours.
This test may be run alone, or as part of a panel to assess levels of metanephrines and other catecholamine-related compounds.
It is essential to consult with the ordering provider prior to sample collection, as some special preparation may be required.
The interpretation of 3-MT test results requires careful consideration of various factors, including age, gender, and specific clinical context. Reference ranges and cut-off values may vary depending on the analytical method used and the population studied.
As a point of reference, one lab reports optimal levels of 3-MT in a 24 hour urine sample as: 122-278 nmol/g creatinine. [12.]
Excessively high or low levels may indicate an issue with dopamine metabolism and require further assessment.
Elevated 3-MT levels, particularly in the setting of symptoms of high dopamine, warrant further assessment.
Elevated 3-MT levels may be associated with neuroblastoma in children, pheochromocytoma, other dopamine-producing tumors, or in schizophrenia.
Decreased 3-MT levels may be associated with Parkinson’s disease or ADHD. [5.]
In addition to 3-MT (3-methoxytyramine), several other biomarkers are closely related and often measured in conjunction to provide a comprehensive assessment of catecholamine metabolism and associated disorders.
Catecholamines including dopamine, norepinephrine, and epinephrine, are the primary neurotransmitters and hormones involved in the sympathetic nervous system.
Measurement of these compounds and their metabolites can provide insights into the underlying pathophysiology of various conditions such as pheochromocytoma, neuroblastoma, and cardiovascular disorders.
Metanephrines including normetanephrine and metanephrine are metabolites of norepinephrine and epinephrine, respectively.
Elevated levels of these biomarkers are commonly observed in pheochromocytoma and paraganglioma, making them valuable diagnostic tools for these conditions.
VMA and HVA are end-products of catecholamine metabolism. While their clinical utility has been somewhat superseded by more specific biomarkers, they can still provide complementary information, particularly in the evaluation of neuroblastoma and certain neurological disorders.
A healthy diet and lifestyle are foundational for healthy dopamine levels.
Lack of sleep can disrupt natural dopamine rhythms and reduce dopamine sensitivity in the brain, leading to excessive sleepiness and reduced alertness.
Establishing a consistent sleep schedule and practicing good sleep hygiene can help regulate dopamine levels.
Research shows that listening to enjoyable music can stimulate the release of dopamine in the brain.
Consume foods rich in the amino acid tyrosine, a precursor for dopamine production, such as dairy products, eggs, beans, whole grains, beef, lamb, chicken, fish, and nuts. [9.]
Combine them with ample fruits and vegetables for their high antioxidant quantity.
Limit intake of saturated fats, as diets high in saturated fat may dampen dopamine signaling and release. [2.]
Regular physical activity has been shown to increase dopamine levels in the brain. For example, individuals who engaged in a daily yoga practice over 3 months showed a significant increase in dopamine levels. [11.]
Exercise can improve mood and motivation, which are influenced by dopamine.
Positive social interactions and feelings of social reward can stimulate dopamine release in the brain's reward system. [7.]
Practicing mindfulness meditation, deep breathing, massage, etc. can support healthy dopamine levels. [6.]
Chronic stress can lead to dysregulation of dopamine levels and impaired dopamine signaling in the brain. [3.]
In particular, meditation has been found to increase dopamine levels in the brain, potentially improving focus and reducing stress. [6.]
Processed foods often contain high levels of saturated fats, which may disrupt dopamine signaling and release. [2.]
Dietary sugar also has strong effects on the dopamine system. Eating sugar triggers dopamine release, reinforcing sugar consumption. Over time, high sugar diets diminish taste sensitivity and weaken dopamine-related satiety signals, leading to overeating and weight gain. [10.]
Click here to compare testing options and order testing to assess dopamine processing.
[1.] 3MT - Overview: 3-Methoxytyramine, 24 Hour, Urine. @mayocliniclabs. Published 2019. Accessed June 7, 2024. https://www.mayocliniclabs.com/test-catalog/overview/65157
[2.] Barnes CN, Wallace CW, Jacobowitz BS, Fordahl SC. Reduced phasic dopamine release and slowed dopamine uptake occur in the nucleus accumbens after a diet high in saturated but not unsaturated fat. Nutr Neurosci. 2022 Jan;25(1):33-45. doi: 10.1080/1028415X.2019.1707421. Epub 2020 Jan 9. PMID: 31914869; PMCID: PMC7343597.
[3.] Bloomfield MA, McCutcheon RA, Kempton M, Freeman TP, Howes O. The effects of psychosocial stress on dopaminergic function and the acute stress response. Elife. 2019 Nov 12;8:e46797. doi: 10.7554/eLife.46797. PMID: 31711569; PMCID: PMC6850765.
[4.] Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán Mejía G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9730467. doi: 10.1155/2016/9730467. Epub 2015 Dec 6. PMID: 26770661; PMCID: PMC4684895.
[5.] khan M zahid, nawaz W. The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system. Biomedicine & Pharmacotherapy. 2016;83:439-449. doi:https://doi.org/10.1016/j.biopha.2016.07.002
[6.] Kjaer TW, Bertelsen C, Piccini P, Brooks D, Alving J, Lou HC. Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res. 2002 Apr;13(2):255-9. doi: 10.1016/s0926-6410(01)00106-9. PMID: 11958969.
[7.] Krach S, Paulus FM, Bodden M, Kircher T. The rewarding nature of social interactions. Front Behav Neurosci. 2010 May 28;4:22. doi: 10.3389/fnbeh.2010.00022. PMID: 20577590; PMCID: PMC2889690.
[8.] Li L, Zhao Z, Ma J, et al. Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson’s Disease: A Cross-Sectional Study. Frontiers in Neuroscience. 2020;14. doi:https://doi.org/10.3389/fnins.2020.00505
[9.] Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatr Suppl. 1994 Dec;407:86-8. doi: 10.1111/j.1651-2227.1994.tb13461.x. PMID: 7766968.
[10.] May CE, Rosander J, Gottfried J, Dennis E, Dus M. Dietary sugar inhibits satiation by decreasing the central processing of sweet taste. Ramaswami M, Dulac C, Ramaswami M, Keene AC, eds. eLife. 2020;9:e54530. doi:https://doi.org/10.7554/eLife.54530
[11.] Pal R, Singh SN, Chatterjee A, Saha M. Age-related changes in cardiovascular system, autonomic functions, and levels of BDNF of healthy active males: role of yogic practice. Age (Dordr). 2014;36(4):9683. doi: 10.1007/s11357-014-9683-7. Epub 2014 Jul 11. PMID: 25012275; PMCID: PMC4150910.
[12.] Rupa Health. Comprehensive Neurotransmitters Sample Report.pdf. Google Docs. Accessed June 7, 2024. https://drive.google.com/file/d/1Zk2T30HvTiA7EpPoqfNbaCBs_fYn69MR/view
[13.] Salimpoor, V., Benovoy, M., Larcher, K. et al. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci 14, 257–262 (2011). https://doi.org/10.1038/nn.2726
[14.] Seo D, Patrick CJ, Kennealy PJ. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. Aggress Violent Behav. 2008 Oct;13(5):383-395. doi: 10.1016/j.avb.2008.06.003. PMID: 19802333; PMCID: PMC2612120.
[15.] Smy L, Kushnir MM, Frank EL. A high sensitivity LC-MS/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine. J Mass Spectrom Adv Clin Lab. 2021 Aug 5;21:19-26. doi: 10.1016/j.jmsacl.2021.08.001. PMID: 34820673; PMCID: PMC8601001.
[16.] Sonne J, Goyal A, Lopez-Ojeda W. Dopamine. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535451/
[17.] Sotnikova TD, Beaulieu JM, Espinoza S, Masri B, Zhang X, Salahpour A, Barak LS, Caron MG, Gainetdinov RR. The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One. 2010 Oct 18;5(10):e13452. doi: 10.1371/journal.pone.0013452. Erratum in: PLoS One. 2010;5(10) doi: 10.1371/annotation/a2019934-b1cc-4781-80cb-9e09fc7ff6dc. PMID: 20976142; PMCID: PMC2956650.
[18.] Verly IRN, Matser YAH, Leen R, Meinsma R, Fiocco M, Koster J, Volckmann R, Savci-Heijink D, Cangemi G, Barco S, Valentijn LJ, Tytgat GAM, van Kuilenburg ABP. Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. JCO Precis Oncol. 2022 Jan;6:e2000447. doi: 10.1200/PO.20.00447. PMID: 35085004; PMCID: PMC8830522.
[19.] Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J, Benveniste H, Kim R, Thanos PK, Ferré S. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci. 2012 May 9;32(19):6711-7. doi: 10.1523/JNEUROSCI.0045-12.2012. PMID: 22573693; PMCID: PMC3433285.
[20.] Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009 Sep 9;302(10):1084-91. doi: 10.1001/jama.2009.1308. Erratum in: JAMA. 2009 Oct 7;302(13):1420. PMID: 19738093; PMCID: PMC2958516.